What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias
Hemato, ISSN: 2673-6357, Vol: 4, Issue: 2, Page: 112-134
2023
- 44Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures44
- Readers44
- 44
- Mentions2
- Blog Mentions1
- 1
- News Mentions1
- 1
Most Recent Blog
Hemato, Vol. 4, Pages 112-134: What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias
Hemato, Vol. 4, Pages 112-134: What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias Hemato doi: 10.3390/hemato4020011 Authors: Marco Pizzi Carmela Gurrieri Attilio
Most Recent News
Reports on Myeloid Leukemia Findings from University of Padua Provide New Insights (What's New in the Classification, Diagnosis and Therapy of Myeloid Leukemias)
2023 APR 19 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Hematology Daily -- Investigators discuss new findings in myeloid leukemia. According to
Article Description
Myeloid leukemias are a broad group of hematological disorders, characterized by heterogeneous clinical and biological features. In recent years, unprecedented genetic discoveries and clinical–biological correlations have revolutionized the field of myeloid leukemias. The most relevant changes have specifically occurred in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), chronic myeloid leukemia (CML) and myeloid neoplasms (MNs) with eosinophilia. The recently published International Consensus Classification (ICC) of myeloid neoplasms has addressed these changes, providing an updated framework and revised diagnostic criteria for such entities. This is also the aim of the 5th edition of the WHO classification of hematopoietic tumors, whose preliminary version was published in 2022. Parallel to this, new therapeutic options and novel molecular targets have changed the management of many myeloid entities, including AML and CML. This review aims to address the most relevant updates in the classification and diagnosis of AML, CMML, CML and MNs with eosinophilia. The state of the art of treatment and future therapeutic options for such disorders are also discussed.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know